Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.

ABSTRACT:

Introduction

Once-weekly (OW) semaglutide was associated with clinically relevant improvements in glycaemic control and body weight versus comparators in the SUSTAIN randomised controlled trials (RCTs). SURE UK, which is one of a series of individual studies that comprise the SURE programme, evaluated the use of OW semaglutide in a real-world patient population with type 2 diabetes (T2D) in the UK.

Methods

In this prospective, observational study, adults (≥ 18 years) with ≥ 1 documented glycated haemoglobin (HbA_1c) value ≤ 12 weeks before semaglutide initiation were enrolled. The primary endpoint was change in HbA_1c from baseline to end of study (EOS; ~ 30 weeks, although due to the COVID-19 pandemic, visits up to week 52 were permitted). Secondary endp

SUBMITTER: Holmes P 

PROVIDER: S-EPMC8475854 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature